**TABLES**

| | SP-MC | 2L-PEG | 1L-PEG | p |
|---|---|---|---|---|
| **Age** | 51.76642 | 53.47965 | 50.09719 | 0,32 |
| **IBD** | UC: 12, CD: 18, IBD-U: 1 | UC: 16, CD: 11, IBD-U: 1 | UC: 16, CD: 14, IBD-U: 3 | 0,45 |
| **UC phenotype (Montreal)** | E1: 1 (3'2%), E2: 6 (19'3%), E3: 5 (16,12%) | E1: 2 (7'1%), E2: 6 (21'4%), E3: 8 (33,3%) | E1: 2 (6%), E2: 8 (24'2%), E3: 6 (18'1%) | 0,94 |
| **CD phenotype (Montreal)** | L1: 6 (19'3%), L2: 7 (22'5%), L3: 5 (16'12%) | L1: 3 (10'7%), L2: 0 (0%), L3: 8 (28'5%) | L1: 4 (12'1%), L2: 3 (9%), L3: 6 (18'18%) | 0,11 |
| **Comorbidity** | | | | |
| Diabetes | Yes: 4 (12'9%), No: 27 (87'1%) | Yes: 4 (14'2%), No: 24 (85'8%) | Yes: 3 (9%), No: 30 (91%) | 0,80 |
| Obesity | Yes: 9 (29%), No: 22 (71%) | Yes: 7 (25%), No: 21 (75%) | Yes: 6 (18'18%), No: 27 (81'81%) | 0,58 |
| Chronic Kidney Disease | Yes: 1 (3'2%), No: 30 (96'8%) | Yes: 1 (3'5%), No: 27 (96'5%) | Yes: 2 (6%), No: 31 (93'9%) | 0,83 |
| Other comorbidities (arterial hypertension, dyslipidemia…) | Yes: 11 (35'4%), No: 20 (64'5%) | Yes: 7 (25%), No: 21 (75%) | Yes: 6 (22'2%), No: 27 (81'8%) | 0,34 |
| **IBD treatment** | | | | |
| No immunosuppresive treatment | 15 (48'3%) | 13 (46'4%) | 20 (60,6%) | 0.37 |
| Immunomodulator | 7 (22'5%) | 7 (25%) | 4 (12'1%) | |
| TNFi | 5 (16'2%) | 3 (12%) | 4 (12'1%) | |
| Vedolizumab | 1 (3'2%) | 2 (7'1%) | 1 (3%) | |
| Ustekinumab | 0 (0%) | 0 (0%) | 0 (0%) | |
| Clinical trial drug | 3 (9'6%) | 0 (0%) | 0 (0%) | |
| Tofacitinib | 0 (0%) | 1 (3'5%) | 1 (3%) | |
| Combination therapy (TNFi + IMM) | 0 (0%) | 3 (12%) | 3 (9%) | |
| + 5ASA | 15 (48'3%) | 15 (53'5%) | 16 (48'4%) | 0.9 |
| + corticosteroids | 2 (6'4%) | 4 (14'2%) | 2 (6%) | 0.45 |
| Low-fibre diet | Yes: 30 No: 1 | Yes: 26 No: 1 | Yes: 33 No: 0 | 0,55 |

| | | | | |
|---|---|---|---|---|
| Symptoms during preparation | Yes: 13<br>No: 18 | Yes: 11<br>No: 16 | Yes: 21<br>No: 11 | 0,08 |
| Stenosis | No: 32 (96,9%). Yes: 1 (3,1%) | No: 26 (92,8%)<br>Yes: 2 (7,2%) | No: 26 (83,8%)<br>Yes: 5 (6,2%) | 0,09 |
| Endoscopic disease activity | No: 15<br>Yes: 16 | No: 14<br>Yes: 13 | No: 18<br>Yes: 15 | 0,74 |
| UC (MES) | 2 (SD 1.41) | 1.5 (SD 0.7) | 1.5 (SD 0.7) | |
| CD (SES-CD) | 6 (SD 2.82) | 8.5 (SD 7.77) | 7.5 (SD 6.9) | |
| Time from preparation to colonoscopy | 7h (SD 3,37) | 6,72h (SD 2,49) | 7,8h (SD 3,47) | 0,72; 0,44 and 0,27 respectively |

**Table 1:** Baseline characteristics of the study population.

| | Variable | SP-MC | 2L-PEG | 1L-PEG | p |
|---|---|---|---|---|---|
| **Efficacy** | % TQC | 87% | 85’74% | 84’8% | 0.8, 0.97 and 0.83 respectively |
| | % THQC | 77’4% | 53’5% | 63’6% | 0.079, 0.12 and 0.81 respectively |
| | % QC right-colon BBPS | 93’5% | 89’29% | 87’8% | 0.44, 0.84 and 0.57, respectively |
| | % QC transverse-colon BBPS | 100% | 89’29% | 93’94% | 0.10, 0.14 and 0.84 respectively |
| | · %QC left-colon BBPS | 96’7% | 96’4% | 96’9% | 0.98, 0.91 and 0.92 respectively |
| **Tolerability** | Questionnaire (Scale 1-10) | 9.93 SD 0.35 | 9.59 SD 1.42 | 8.62 SD 2.53 | **p=0,006**; p=0,55 and **p=0,02** respectively |
| **Safety** | | | | | |
| Symptoms pre-colonoscopy | Abdominal pain, nausea, vomiting… self-reported via questionnaire | Yes: 13 No: 18 | Yes: 11 No: 16 | Yes: 21 No: 11 | 0,08 |
| Symptoms post-colonoscopy | Abdominal pain, nausea, vomiting… self-reported via questionnaire | Yes: 4 No: 27 | Yes: 5 No: 23 | Yes: 2 No: 31 | p=0,33 |
| Laboratory: | Glu | 75.5 (SD 13.7) | 78 (SD 18) | 79.35 (SD 15.4) | **p<0,0001** for Na in SP, rest of p values for all parameters are nS. |
| | Cr | 0.78 (SD 0.14) | 0.7 (SD 0.21) | 0.78 (SD 0.16) | |
| | GFR | 88.34 (SD 4.09) | 87.57 (SD 7.7) | 87,69 (SD 7,7) | |
| | Na | 138,7 (SD 2,19) | 141,25 (SD 2,78) | 142,006 (SD 2,66) | |
| | K | 3.62 (SD 0.36) | 3.86 (SD 0.48) | 3.8 (SD 0.48) | |

| | | | | | |
|---|---|---|---|---|---|
| | Questionnaire (Scale 1-10) | 7.32 (SD 2.74) | 7.48 (SD 2.7) | 6.1 (SD 2.87) | |
| Satisfaction | Questionnaire (Scale 1-10) | 9,64 SD: 1,08 | 9,48 SD 0,84 | 7,93 SD 2,6 | 0,38; 0,25 and 0,05; respectively |
| Easiness to understand instrucions | Questionnaire (yes/no) | 30/1 | 22/6 | 14/19 | **0,01;** 0,1; and **0,0001** respectively |
| Willingness to retake | Questionnaire (yes/no) | Yes: 96.7% No: 3,3% | Yes: 78'5% No: 22'5% | Yes: 42'4% No: 57'6% | **0,0001**; 0,33 and **0,0001** respectively |

**Table 2:** Complete results regarding efficacy, safety, tolerability and satisfaction of SP vs 1L-PEG vs 2L-PEG.